Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Non-Small Cell Lung Cancer、EGFR Sensitive Mutation”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Not Yet RecruitingNCT06182761
What this trial is testing

Sunvozertinib Combined With Anlotinib in Local Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
NSCLC
Shanghai Zhongshan Hospital 45
Large-scale testing (Phase 3)Looking for participantsNCT06041776
What this trial is testing

Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations

Who this might be right for
Non-Small Cell Lung CancerEGFR Sensitive MutationAdjuvant Therapy
Betta Pharmaceuticals Co., Ltd. 570
Testing effectiveness (Phase 2)Looking for participantsNCT05579366
What this trial is testing

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

Who this might be right for
High Grade Epithelial Ovarian CancerHigh Grade Serous Ovarian CancerPrimary Peritoneal Carcinoma+12 more
Genmab 884
Early research (Phase 1)Study completedNCT02157883
What this trial is testing

Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)

Who this might be right for
Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
AstraZeneca 39
Testing effectiveness (Phase 2)Study completedNCT01802632
What this trial is testing

AZD9291 First Time In Patients Ascending Dose Study

Who this might be right for
Advanced Non Small Cell Lung CancerAdvanced (Inoperable) Non Small Cell Lung Cancer
AstraZeneca 603
Testing effectiveness (Phase 2)UnknownNCT03396185
What this trial is testing

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Who this might be right for
EGFR Gene MutationNon Small Cell Lung Cancer Stage IIIANon Small Cell Lung Cancer Stage IIIB
Betta Pharmaceuticals Co., Ltd. 30
Not applicableNot Yet RecruitingNCT07697716
What this trial is testing

In Vitro NSCLC EGFR-Mutant Models for Drug Sensitivity Testing

Who this might be right for
Carcinoma, Non-Small-Cell LungEGFR Gene Mutation
Fondazione Policlinico Universitario Agostino Gemelli IRCCS 30
Not applicableUnknownNCT06481566
What this trial is testing

Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial

Who this might be right for
Non-small Cell Lung Cancer
Chongqing University Cancer Hospital 30
Not applicableStudy completedNCT00831454
What this trial is testing

Identification of EGFR-TKIs Sensitivity or Resistance Markers in NSCLC May Help in Optimal Patient Selection

Who this might be right for
NON-SMALL-CELL LUNG CANCER
Armando Santoro, MD 51
Testing effectiveness (Phase 2)Looking for participantsNCT06709859
What this trial is testing

Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Shandong Public Health Clinical Center 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06530719
What this trial is testing

Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery

Who this might be right for
Lung NeoplasmsLung Cancer, Nonsmall Cell
Jin Ying 54
Testing effectiveness (Phase 2)Study completedNCT01922583
What this trial is testing

AUY922 in Patient With Stage IV NSCLC

Who this might be right for
Non-small Cell Lung Cancer (NSCLC)
National Taiwan University Hospital 31
Large-scale testing (Phase 3)Looking for participantsNCT05382728
What this trial is testing

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Who this might be right for
NSCLCEGFR Activating Mutation
TYK Medicines, Inc 680
Testing effectiveness (Phase 2)Looking for participantsNCT06355609
What this trial is testing

Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR Mutant Advanced NSCLC-RW

Who this might be right for
Non-small Cell Lung Cancer
Hunan Province Tumor Hospital 100
Large-scale testing (Phase 3)Looking for participantsNCT06043973
What this trial is testing

Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance

Who this might be right for
Advanced Non-small Cell Lung Cancer
Qianfoshan Hospital 98
Large-scale testing (Phase 3)Looking for participantsNCT06735391
What this trial is testing

A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations

Who this might be right for
Locally Advanced or Metastatic Non-squamous NSCLCHarboring EGFR Sensitive Mutations NSCLCPreviously Untreated Systematically NSCLC
Shanghai JMT-Bio Inc. 516
Large-scale testing (Phase 3)Not Yet RecruitingNCT06048315
What this trial is testing

A Single Center, Single Arm Clinical Study on the Treatment of Advanced Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations and Failed EGFR TKIs With the Combination of Enrotinib and Paclitaxel Monoclonal Antibody

Who this might be right for
Lung CancerTKI ResistanceEGFR Sensitive Mutation+2 more
Degan Lu 52
Testing effectiveness (Phase 2)Looking for participantsNCT06652048
What this trial is testing

High-dose Furmonertinib or Combined With Chemotherapy in EGFR-mutant Advanced NSCLC After Disease Progression on Third-generation EGFR-TKI

Who this might be right for
Non-Small Cell Lung Cancer
Jialei Wang 60
Not applicableUnknownNCT01775943
What this trial is testing

Efficacy of EGFR TKIs in Patients With Rare EGFR-mutated NSCLC

Who this might be right for
Lung Neoplasms
Ulsan University Hospital 90
Testing effectiveness (Phase 2)UnknownNCT03153358
What this trial is testing

Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation

Who this might be right for
Lung Cancer Stage IV
Sichuan Cancer Hospital and Research Institute 60
Next Page